Evidence map›Paper›PMID 30429021›Full record

ArticleLung cancer (Amsterdam, Netherlands)2018

Receipt of recommended surveillance with imaging in elderly survivors of early stage non-small cell lung cancer.

Jyoti Malhotra, David Rotter, Salma K Jabbour, Joseph Aisner, Yong Lin, Sharon Manne, Kitaw Demissie

Open access · greenAbstract read
In one paragraph

Article in Lung cancer (Amsterdam, Netherlands), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jyoti MalhotraRutgers Cancer Institute of New Jersey, New Brunswick, NJ, United States. Electronic address: Jyoti.malhotra@rutgers.edu.
David RotterRutgers Cancer Institute of New Jersey, New Brunswick, NJ, United States.
Salma K JabbourRutgers Cancer Institute of New Jersey, New Brunswick, NJ, United States.
Joseph AisnerRutgers Cancer Institute of New Jersey, New Brunswick, NJ, United States.
Yong LinDepartment of Epidemiology, Rutgers School of Public Health, Piscataway, NJ, United States.
Sharon ManneRutgers Cancer Institute of New Jersey, New Brunswick, NJ, United States.
Kitaw DemissieRutgers Cancer Institute of New Jersey, New Brunswick, NJ, United States; Department of Epidemiology, Rutgers School of Public Health, Piscataway, NJ, United States.
Rutgers Cancer Institute of New JerseyRutgers, The State University of New Jersey · US

Funding

Dr. Salma Jabbour’s NCI Research Specialist (Clinician Scientist) Award (R50)R50CA275877 · NCI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI Salma Jabbour · 2023 to 2026
$785k
NCI NIH HHS R50 CA275877
6 · The paper itself

Abstract

purposeEarly-stage lung cancer survivorsremain at high risk for recurrence or second cancers. We measured the rates and determinants of regular surveillance imaging in early-stage non-small cell lung cancer (NSCLC) survivors.

methodsPatients (diagnosed 2001-2011) with resected stage I and II NSCLC were identified from the Surveillance Epidemiology and End Results (SEER)-Medicare linked database. Patients were censored at recurrence/second cancer diagnosis, loss to follow-up or death. Receipt of a scan during the surveillance periods of 7-18, 19-30, 31-42 and 43-60 months from date of surgery was assessed.

resultsOf 10,680 survivors assessed during the 18-month surveillance period, 71% received imaging in first 18 months. Only 56% and 43% continued to receive regular imaging by 30-month and 60-month of follow-up, respectively. Survivors were less likely to receive imaging if they were older, black, unmarried, received no adjuvant therapy, had stage I disease (vs. stage II) or were diagnosed before 2006. In adjusted analysis, survivors who received recommended imaging up to 18 months from surgery experienced better survival compared to survivors who did not (HR 0.92; 95% CI 0.85-0.99). Survival benefit was also observed in survivors who underwent regular imaging up to 5 years from surgery (HR 0.68; 95% CI 0.60-0.78).

conclusionsMore than half the lung cancer survivors received less than the recommended long-term surveillance imaging. Long-term adherence to surveillance is associated with improved survival. Our study provides evidence to support the current clinical guidelines for surveillance for lung cancer survivors that are primarily consensus-based at present.

Indexed as

AgedAged, 80 and overCarcinoma, Non-Small-Cell LungCohort StudiesCombined Modality TherapyFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMedicareNeoplasm Recurrence, LocalNeoplasm StagingSEER ProgramSurvivorsUnited StatesLung cancerSurveillanceSurvivor

Identifiers

PMID30429021
PMCPMC10865993
OpenAlexW2895117612

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.